#USA #Minneapolis #Bio-Techne #Spatial Biology #RNA Probes

Bio-Techne Expands RNAscope Probes for Enhanced Spatial Biology

Bio-Techne, a prominent name in life science tools and reagents, recently unveiled its extensive new range of RNAscope probes designed for studying human and mouse transcriptomes. This launch is set against a backdrop of increased demand for spatial biology research, particularly in the context of developing next-generation therapies and diagnostics.

These newly introduced RNAscope probes are engineered to provide exceptional spatial precision coupled with industry-leading sensitivity and specificity. With more than 70,000 unique probes spread across 450 different species now available, Bio-Techne aims to deliver unrivaled insight into cell biology and pathology.

The RNAscope technology is recognized as a gold standard in spatial biology, offering researchers an unprecedented single-cell perspective into disease mechanisms and responses to therapies. This feature has garnered Bio-Techne's probes over 12,000 citations within the clinical and translational research domains, underpinning their importance in advancing contemporary biomedical science.

Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, emphasized the company's commitment to facilitating innovative research solutions. He stated, "Empowering our customers with precise and scalable solutions to advance translational research and precision medicine is central to our mission." The new RNAscope probes are strategically designed to simplify the validation process for RNA biomarkers derived from single-cell genomics and spatial discovery initiatives, positioning researchers for success as they transition from discovery to practical applications in clinical settings.

Researchers will find a variety of formats available for these probes, including both manual and automated options. This flexibility is mirrored in their compatibility with automated systems such as the Lunaphore COMET™, streamlining workflows for translating RNA and multiomic biomarkers from late-phase discovery into clinical assay development.

In conjunction with these probe offerings, Bio-Techne also provides access to its RD Systems antibodies, helping researchers to highlight alterations in cell phenotypes and functional states effectively. This comprehensive toolset enhances the understanding of complex biological interactions and improves the reliability of scientific inquiries.

The practical implications of this innovation are vast. With a rapidly expanding array of probe options, scientists can more readily tackle the challenges associated with biomarker validation and preclinical studies that are vital to therapeutic advancements. Bio-Techne's commitment to innovation in spatial biology will likely lead to improved healthcare outcomes and a greater understanding of disease processes.

The RNAscope probes are now available for purchase through the Bio-Techne website, granting researchers instant access to these essential tools. As the field of spatial biology continues to evolve, Bio-Techne's contribution is expected to play a crucial role in shaping future research directions and enhancing disease diagnostics and treatment strategies.

Bio-Techne Corporation, listed on NASDAQ as TECH, is dedicated to supplying novel tools and bioactive reagents that significantly aid research and clinical diagnostics. With over 1.2 billion dollars in net sales for the fiscal year 2024, the company demonstrates both market leadership and a commitment to advancing global scientific exploration through their extensive range of products and services.

For further details, you can visit Bio-Techne's website or follow them on social media.